4D Molecular Therapeutics Expands Leadership Team with Appointments and Promotions of Key Executives

  • Company adds manufacturing and quality expertise and broad
    financial, operational and legal experience with the appointments of
    Fred Kamal, PhD as chief technical officer and head of regulatory and
    quality and of August Moretti as chief financial officer
  • Company announces promotions of Peter Francis, MD, PhD to chief
    medical officer and Theresa Janke to chief operating officer

EMERYVILLE, Calif.–(BUSINESS WIRE)–4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector
Evolution for adeno-associated virus (AAV) gene therapy vector discovery
and product development, announced the appointments of Fred Kamal, PhD,
as chief technical officer, and August Moretti as chief financial
officer. The company also announced the promotions of Peter Francis to
chief medical officer and Theresa Janke to chief operating officer.

“4D continues to execute towards its goal of building a platform and
pipeline of next-generation AAV gene therapy products for patients with
severe genetic diseases, and I am thrilled to further strengthen our
executive team with the appointments of Fred and Augie and the
promotions of Peter and Theresa,” said David Kirn, chairman and chief
executive officer of 4DMT. “These additions build on our strong
foundation as a leader in the gene therapy field. Fred is a seasoned
drug developer and brings technical expertise in AAV gene therapy
manufacturing and quality while Augie brings a wealth of experience in
finance, legal and operations. Peter and Theresa have experience as
leaders in gene therapy clinical research and business operations, and
we are excited to continue leveraging their skills in these expanded
roles.”

Fred Kamal, PhD has over 25 years of experience in the biotechnology
industry, having focused much of his career on manufacturing and
quality. Prior to joining 4DMT, Fred served as senior vice president of
quality and regulatory CMC at Avexis, where he ultimately oversaw the
BLA submission of AVXS-101, a groundbreaking one-time therapy designed
to address the genetic cause of SMA Type 1. Prior to Avexis, Dr. Kamal
was vice president of global quality at Juno Therapeutics and before
that, vice president of global quality at InterMune. Earlier in his
career, he served in various roles of increasing responsibility at
MedImmune, Bayer Health Care and Amgen. Dr. Kamal received his MS and
PhD from American University.

With over 35 years of experience working with life sciences companies,
August Moretti brings broad-based financial, operational and legal
experience to 4DMT. Mr. Moretti joins after previously serving as senior
vice president and chief financial officer at Assertio Therapeutics
(formerly Depomed). Prior to Assertio, he was chief financial officer,
senior vice president and general counsel at Alexza Pharmaceuticals,
Inc. Prior to that, he served as chief financial officer and general
counsel of Alavita, Inc. (formerly Surromed Inc.). Mr. Moretti has
extensive finance experience and has raised more than $1.5 billion of
capital from equity, convertible and secured debt and royalty
monetization. At Alexza and Assertio he was responsible for a combined
50 consecutive quarters of SEC reporting. Mr. Moretti holds a BA degree
in Economics from Princeton University and a JD from Harvard Law School.

Peter Francis, MD, PhD, is an ophthalmologist clinician-scientist with
expertise in ophthalmic genetics and retinal disease. He has served as
principal investigator on several important gene and stem-cell clinical
trials. Dr. Francis joined 4DMT in 2015 as vice president, clinical and
translational R&D and head of ophthalmology therapeutic area. Prior to
4DMT, he was chief medical officer at RetroSense Therapeutics, a gene
therapy company developing optogenetic therapy for eye disease, which
was acquired by Allergan. Peter holds a PhD in ophthalmic genetics from
University College, London. Peter is fellowship trained in retina,
genetics and neuro-ophthalmology.

Theresa Janke has over 18 years of clinical research and operations,
alliance and program management, and business operations experience in
the biopharmaceutical industry. Her work has included oversight of
multiple strategic collaborations and planning and management of
international clinical trials at companies developing complex viral
vector-based oncolytic virus immunotherapies, viral vector-based gene
therapies, and medical devices. She was a founding member of the
management team at 4DMT and is a board member of IGNITE Immunotherapy.
Theresa previously served as senior vice president, Business Operations
& Alliance Management at 4DMT. Prior to 4DMT she served as director of
clinical operations at Jennerex Biotherapeutics. Earlier in her career,
Ms. Janke held roles of increasing responsibility at different divisions
of Abbott, Allergan and Celgene. Theresa holds a BS degree in Biology &
Neuropsychology from the University of California, Santa Barbara.

About 4D Molecular Therapeutics (4DMT)

4DMT is focused on the discovery and development of targeted, customized
and proprietary next-generation AAV gene therapy products for use in
patients with severe genetic diseases with high unmet medical need. Our
robust discovery platform, termed Therapeutic Vector Evolution, empowers
us to create customized gene delivery vehicles to deliver genes
specifically to any tissue or organ in the body, by optimal clinical
routes of administration, at lower doses and with resistance to
pre-existing antibodies. These proprietary and targeted products allow
us to treat both rare genetic diseases and complex large market
diseases. 4DMT is creating a diverse and deep product pipeline through
its own internal 4D products, as well as partnered programs.

About 4DMT’s Therapeutic Vector Evolution

4DMT is advancing the field of targeted and optimized AAV vector
technology by deploying principles of evolution and natural selection to
create vectors that efficiently and selectively target the desired cells
within the diseased human organ via clinically optimal routes of
administration, at manageable doses and with resistance to pre-existing
antibodies in the population. Our Therapeutic Vector Evolution platform
deploys over 100 million unique AAV variants from over 35 unique and
proprietary 4DMT AAV libraries with extensive diversity. After defining
the Target Product Profile, and the associated Target Vector Profile,
4DMT then applies proprietary methods to identify lead vectors from
within our AAV libraries. The result is a customized, novel, and
proprietary pharmaceutical-grade product uniquely designed for targeted
therapeutic gene delivery and efficacy in humans.

Contacts

Media:
Jamie Firmage
[email protected]
415
860-6301

Investors:
Pete Rahmer
Endurance
Advisors
[email protected]
415-515-9763

Mike
Zanoni
Endurance Advisors
[email protected]
610-442-8570

error: Content is protected !!